Sabirnetug (ACU193) - Intravenous (IV)
Early Alzheimer's Disease
Key Facts
Indication
Early Alzheimer's Disease
Phase
Phase 2
Status
Active - ALTITUDE-AD trial ongoing, enrollment completed 2025
Company
About Acumen Pharmaceuticals
Acumen Pharmaceuticals is a public, clinical-stage biotech singularly focused on developing targeted Alzheimer's disease therapies based on the amyloid-beta oligomer (AβO) hypothesis. Its lead candidate, sabirnetug (ACU193), is a first-in-class monoclonal antibody in Phase 2 development, designed for high selectivity to soluble AβOs. The company has built a seasoned leadership team with deep Alzheimer's expertise, secured foundational IP from leading academic institutions, and is advancing a subcutaneous formulation and an Enhanced Brain Delivery platform. With Phase 2 enrollment complete, Acumen is positioned to generate critical efficacy data that could validate its differentiated scientific approach.
View full company profileTherapeutic Areas
Other Early Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| AD04™ | ADvantage Therapeutics | Phase 2 |
| IBC-Ab002 | ImmunoBrain Checkpoint | Phase 1 |
| Lecanemab (Leqembi®) | bioarctic-ab | Approved |
| AL101 / GSK4527226 | Alector | Phase 2 |
| AL002 | Alector | Phase 2 |
| Sabirnetug (ACU193) - Subcutaneous (SC) | Acumen Pharmaceuticals | Phase 1 |